- … show all 0 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A female infant [age at reaction onset not clearly stated] developed mucositis during treatment with sirolimus.
The girl had PHACE (Posterior fossa brain malformations, Haemangiomas, Arterial anomalies, Cardiac defects, and Eye abnormalities) syndrome and treatment-resistant infantile haemangioma (IH). She presented with extensive facial IH complicated by lip ulceration at the age of 3 weeks. She initially received prednisolone and then propranolol. Despite treatment, her IH rapidly progressed and she began treatment with oral sirolimus 1.5 mg/m2 daily at the age of 14 weeks. Her sirolimus was increased to 1.5 mg/m2 twice daily after 4 weeks of therapy. Her propranolol was stopped 6 weeks after beginning sirolimus and her corticosteroids were tapered and withdrawn 13 weeks after starting sirolimus. The sirolimus trough concentration range was 4.3−19.2 ng/mL. During hospitalisation for feeding intolerance, a sirolimus trough concentration of 20.3 ng/mL was noted and her sirolimus dosage ...
- Kaylani S, et al. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatric Dermatology 30: e194-e197, No. 6, Nov-Dec 2013. Available from: URL: http://dx.doi.org/10.1111/pde.12023 - USA CrossRef
Volume 1482, Issue 1 , p 36
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors